Indivior (INDV)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$34.77+1.31%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Broken: Primary pillar broken — SUBLOCADE net revenue growth: 14.0% vs 32% target.
Indivior grows SUBLOCADE revenue 32% year-over-year to $232 million in Q1 2026. Adjusted EBITDA more than doubled to $164 million, beating the 50% growth target. The company raised 2026 revenue guidance to about $1.25 billion. Share repurchases of $175 million support capital return.
Growth could slow if SUBLOCADE sales weaken or competition intensifies. Profit margins might compress if costs rise. Capital allocation could falter if debt levels increase or buybacks pause.
The market prices in about 1% revenue growth and values the stock slightly below our fair value estimate near $41. Our view sees stronger growth and margin expansion than consensus.
Breaks if: Adjusted EBITDA growth falls below 25% YoY
Breaks if: Share repurchases drop below $100 million annually without offsetting capital returns
Full-year revenue guidance falls below $1.2 billion
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a durable compounder with a focus on steady revenue and EBITDA growth. The current thesis state reflects strong recent financial performance, but management's volatility adds an element of uncertainty.
The market currently prices INDV as cheap compared to its peers, with an expectations gap indicating that investors may not fully anticipate the company's potential growth. There is low fragility in the stock, suggesting that current valuations are justified without significant risk of downturn.
Fundamentals are likely to continue improving, as management is on track with its priorities to accelerate revenue and EBITDA growth. However, there is a moderate risk due to the potential for economic factors, such as a weakening jobs report, to impact performance.
The thesis hinges on management's ability to maintain guidance and deliver on growth targets, as well as external factors like sector performance from key competitors. Any reversal in guidance could significantly impact credibility and stock performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports expectations for adjusted EBITDA growth of 50%. Additionally, the plan to accelerate SUBLOCADE net revenue growth further enhances the outlook. There are no new threats identified that could weaken this positive momentum.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on accelerating SUBLOCADE net revenue and dispense unit growth throughout 2026 as part of Phase II of the Indivior Action Agenda.
Stated as a priority in 4 of last 4 quarters. Total SUBLOCADE net revenue grew from $176 million in 2025-Q1 to $253 million in 2026-Q2, a 21% to 32% year-over-year increase per quarter. Full-year 2026 guidance was raised to $1,010 million to $1,050 million from prior $950 million to $990 million. Management's trajectory is delivering with accelerating revenue growth and raised guidance.
“Exceptional operational execution in Phase II – Accelerate – fueled strong SUBLOCADE performance in the quarter.”
“We are encouraged by our first quarter results, which reflect the progress we are making against Phase II of the Indivior Action Agenda – Accelerate.”
“We are now executing Phase II of the Indivior Action Agenda – Accelerate, which includes accelerating SUBLOCADE throughout 2026.”
“Phase II – Accelerate – includes accelerating SUBLOCADE net revenue and dispense unit growth in 2026.”
Breaks if: SUBLOCADE revenue growth falls below 15% YoY
Focus on accelerating SUBLOCADE net revenue and dispense unit growth throughout 2026 as part of Phase II of the Indivior Action Agenda.
Stated as a priority in 4 of last 4 quarters. Total SUBLOCADE net revenue grew from $176 million in 2025-Q1 to $253 million in 2026-Q2, a 21% to 32% year-over-year increase per quarter. Full-year 2026 guidance was raised to $1,010 million to $1,050 million from prior $950 million to $990 million. Management's trajectory is delivering with accelerating revenue growth and raised guidance.
“Exceptional operational execution in Phase II – Accelerate – fueled strong SUBLOCADE performance in the quarter.”
“We are encouraged by our first quarter results, which reflect the progress we are making against Phase II of the Indivior Action Agenda – Accelerate.”
“We are now executing Phase II of the Indivior Action Agenda – Accelerate, which includes accelerating SUBLOCADE throughout 2026.”
“Phase II – Accelerate – includes accelerating SUBLOCADE net revenue and dispense unit growth in 2026.”
Overall, INDV shows promise with strong fundamentals and a favorable sector backdrop, but it faces risks that could affect its trajectory. Not investment advice.